TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30904875

Group type: EXPERIMENTAL
Intervention: Pterygopalatine ganglion pulsed radiofrequency (PRF) treatment at 42°C for 360 seconds
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nerve block (NB) treatment with a mixture of steroids and local anaesthetics
Number of subjects: 80
Study: 30265305

Group type: EXPERIMENTAL
Intervention: Fertility education (intervention group)
Number of subjects: 1455

Group type: COMPARATOR
Intervention: Healthy pre-pregnancy information (control group 1)
Number of subjects: 1455

Group type: COMPARATOR
Intervention: Family policies in Japan (control group 2)
Number of subjects: 1455
Study: 27454855

Group type: EXPERIMENTAL
Intervention: Mixed Mediterranean-type meal (MMM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: High-saturated fatty acid meal (HSFAM)
Number of subjects: 28
Study: 25361376

Group type: EXPERIMENTAL
Intervention: Haptic biofeedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bathroom scale training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Verbal instruction
Number of subjects: 30
Study: 22498220

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 34887

Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 34887

Group type: EXPERIMENTAL
Intervention: Vitamin E plus Selenium
Number of subjects: 34887

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34887
Study: 20499024

Group type: EXPERIMENTAL
Intervention: Combination (500 mg vitamin C and 200 mg Tocovid)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tocotrienol (200 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 17571481

Group type: EXPERIMENTAL
Intervention: Bupivacaine 10mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine 8mg + Fentanyl 20 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine 6mg + Fentanyl 20 microg
Number of subjects: 60
Study: 16173084

Group type: EXPERIMENTAL
Intervention: Scheduled clinician-initiated calls
Number of subjects: 44

Group type: COMPARATOR
Intervention: Requested by the patient
Number of subjects: 44
Study: 12574428

Group type: EXPERIMENTAL
Intervention: Neural activity in a unique network involving bilateral dorsolateral prefrontal and posterior cortices
Number of subjects: 2

Group type: COMPARATOR
Intervention: Left hemisphere network of regions including prefrontal and temporal cortices
Number of subjects: 2
Study: 10333106

Group type: EXPERIMENTAL
Intervention: Dry Drops (lyophilisate with HPMC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional eye drops (same polymer and electrolytes)
Number of subjects: 32
Study: 8960830

Group type: EXPERIMENTAL
Intervention: Intensified Conventional Treatment (ICT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 91
Study: 1754635

Group type: EXPERIMENTAL
Intervention: ritanserin (5-10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 6923655

Group type: EXPERIMENTAL
Intervention: Calcium heparin, 5000 IU s.c. every 8 hr for 7 days, first administration 2 hr before surgery
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 29
Study: 6709383

Group type: EXPERIMENTAL
Intervention: Imaginal strategy treatment (response group) - trained to imagine pleasant scenes including muscular relaxation and deep breathing.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaginal strategy treatment (stimulus group) - trained to imagine scenes with many stimulus details.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study: 31852846

Group type: EXPERIMENTAL
Intervention: RN168 1 mg/kg every other week (Q2wk)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: RN168 3 mg/kg every other week (Q2wk)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: RN168 higher doses (not specified)
Number of subjects: 37
Study: 30423846

Group type: EXPERIMENTAL
Intervention: Healthy Eating Pattern (HEP) cycling (Dietary Approaches to Stop Hypertension-style or Mediterranean-style)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Healthy Eating Pattern (HEP) cycling
Number of subjects: 60
Study: 26863596

Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid photodynamic therapy (ALA‐PDT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Vehicle photodynamic therapy (VEH‐PDT)
Number of subjects: 93
Study: 24997559

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg for participants ≥18 years, 50 mg for those <18 years) and Lansoprazole (60 mg for participants ≥18 years, 30 mg for those <18 years)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 22834121

Group type: EXPERIMENTAL
Intervention: Ladasten
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20139792

Group type: EXPERIMENTAL
Intervention: Nonwear threshold of 90 minutes
Number of subjects: 107

Group type: COMPARATOR
Intervention: Nonwear threshold of 60 minutes
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Mean daily activity counts
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Mean daily minutes of moderate to vigorous physical activity (MVPA)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: MVPA bout minutes per wear hour
Number of subjects: 107
Study: 17932823

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine solution
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 114
Study: 16041592

Group type: EXPERIMENTAL
Intervention: SENSE MRI
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional MRI
Number of subjects: 31
Study: 12488296

Group type: EXPERIMENTAL
Intervention: Interval debulking surgery (IDS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Primary debulking surgery (PDS)
Number of subjects: 34
Study: 10372468

Group type: EXPERIMENTAL
Intervention: BPD assumptions (PDBQ ratings)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PDBQ ratings after viewing an emotional video fragment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BPD assumptions mediating relationship with self-reported etiological factors
Number of subjects: 16
Study: 8906005

Group type: EXPERIMENTAL
Intervention: Ritodrine infusion
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 1861962

Group type: EXPERIMENTAL
Intervention: Duraphat (2.26% fluoride), n = 206, six-monthly applications
Number of subjects: 495

Group type: COMPARATOR
Intervention: Carex (1.80% fluoride), n = 189, six-monthly applications
Number of subjects: 495
Study: 6621429

Group type: EXPERIMENTAL
Intervention: Experienced teachers
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Novice teachers
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 29846719

Group type: EXPERIMENTAL
Intervention: sucroferric oxyhydroxide 1.0-3.0 g/day
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: sevelamer 2.4-14.4 g/day
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: sucroferric oxyhydroxide or sevelamer
Number of subjects: 549
Study: 28220519

Group type: EXPERIMENTAL
Intervention: Amustaline-treated RBCs (Test)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control RBCs
Number of subjects: 42
Study: 25667293

Group type: EXPERIMENTAL
Intervention: 10% Urea-based cream (UBC) plus best supportive care (BSC)
Number of subjects: 871

Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 871
Study: 22930369

Group type: EXPERIMENTAL
Intervention: Preference-consistent information sharing with partners stating they understood the participants' preference.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preference-consistent information sharing with partners stating they did not understand the participants' preference.
Number of subjects: 0
Study: 19765131

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 ml diluted in physiologic saline) given as intravenous infusion once daily for 10 days
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Placebo (saline) given as intravenous infusion once daily for 10 days
Number of subjects: 1060
Study: 17515729

Group type: EXPERIMENTAL
Intervention: Blood Volume Tracking (BVT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard Hemodialysis (SHD)
Number of subjects: 28
Study: 15570253

Group type: COMPARATOR
Intervention: G‐CSF
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: GM‐CSF plus G‐CSF
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sequential administration of G‐CSF followed by GM‐CSF 6 days later
Number of subjects: 35
Study: 11148742

Group type: EXPERIMENTAL
Intervention: Alpha blocker-finasteride combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study: 10323611

Group type: EXPERIMENTAL
Intervention: Bioengineered skin substitute (TransCyte)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Topical antibiotics (bacitracin ointment applied 2-3 times daily)
Number of subjects: 21
Study: 8694728

Group type: EXPERIMENTAL
Intervention: 0.25% apraclonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 0
Study: 1836087

Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 0
Study: 6750206

Group type: EXPERIMENTAL
Intervention: Alternate-day steroids (ADS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily steroids (DS)
Number of subjects: 0
Study: 31430023

Group type: EXPERIMENTAL
Intervention: Higher fractional anisotropy in individuals at ultra-high risk for psychosis
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Lower fractional anisotropy in superior longitudinal fasciculus and cingulate gyrus
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Patterns of cognitive functions
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Widespread higher fractional anisotropy
Number of subjects: 116
Study: 28700420

Group type: EXPERIMENTAL
Intervention: 3D video recordings
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2D video recordings
Number of subjects: 100
Study: 27897989

Group type: EXPERIMENTAL
Intervention: Sleep-low strategy (SL), CHO intake: 6 g·kg‐1·day‐1
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (CON), even distribution of CHO intake
Number of subjects: 11
Study: 25200049

Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel
Number of subjects: 113

Group type: COMPARATOR
Intervention: Aspirin plus placebo
Number of subjects: 113
Study: 23111043

Group type: EXPERIMENTAL
Intervention: Training in a simulated exsanguination and cardiac arrest emergency
Number of subjects: 171
Study: 20429797

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 34144

Group type: COMPARATOR
Intervention: Conventional glucose control
Number of subjects: 34144
Study: 18005932

Group type: EXPERIMENTAL
Intervention: One-session exposure treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Five-session exposure treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 40
Study: 15732265

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a 44 mcg once weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a 22 mcg once weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo/22 mcg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo/44 mcg
Number of subjects: 0
Study: 12958848

Group type: EXPERIMENTAL
Intervention: Donepezil capsule (5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Donepezil tablet (5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Donepezil capsule
Number of subjects: 20
Study: 10778658

Group type: EXPERIMENTAL
Intervention: Controlled release formulation A (Tegretol CR, local)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Controlled release formulation B (Tegretol CR, Basel)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional formulation (Tegretol)
Number of subjects: 12
Study: 8832475

Group type: EXPERIMENTAL
Intervention: Bioabsorbable collagen membrane (COLL)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene (ePTFE)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control surgical debridement (DEBR)
Number of subjects: 59
Study: 1428134

Group type: EXPERIMENTAL
Intervention: 1 mg Vitamin K intramuscular (Menadione sodium disulphite) at birth
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.5 mg Vitamin K intramuscular
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1 mg Vitamin K orally
Number of subjects: 100

Group type: COMPARATOR
Intervention: No Vitamin K
Number of subjects: 100
Study: 3883857

Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline 1 mg in 2 mL normal saline
Number of subjects: 19

Group type: COMPARATOR
Intervention: Subcutaneous epinephrine 0.01 mg/kg (0.3 mg maximum)
Number of subjects: 19
Study: 28580884

Group type: EXPERIMENTAL
Intervention: MI-CBT (Motivational Interviewing integrated with Cognitive-Behavioral Therapy)
Number of subjects: 85

Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 85
Study: 30140707

Group type: EXPERIMENTAL
Intervention: Duration of blood glucose (BG) < 3.9 mmol/L
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Body surface area (BSA)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Area under the curve for BG > 7.8 mmol/L
Number of subjects: 121
Study: 26333683

Group type: EXPERIMENTAL
Intervention: Osteochondral autograft
Number of subjects: 40

Group type: COMPARATOR
Intervention: Osteochondral allograft
Number of subjects: 40
Study: 24846622

Group type: COMPARATOR
Intervention: Standard implantation technique with an OVD
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hydroimplantation technique
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 100
Study: 22318706

Group type: EXPERIMENTAL
Intervention: Epoetin beta (EPO)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 20370945

Group type: EXPERIMENTAL
Intervention: Lactulose in liquid (L-L)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Solid lactulose (L-S)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Solid inulin (IN-S)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Inulin (IN-S)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No substrate (NO-S)
Number of subjects: 17
Study: 18568180

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study: 15966619

Group type: EXPERIMENTAL
Intervention: Plain radiography
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Digital subtraction arthrography
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Radionuclide arthrography
Number of subjects: 23
Study: 14583173

Group type: EXPERIMENTAL
Intervention: Hypoglycemic clamp (approximately 50 mg/dl)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Euglycemic clamp (approximately 90 mg/dl)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Exercise bouts at 50% VO2max
Number of subjects: 47

Group type: COMPARATOR
Intervention: Basal leptin levels
Number of subjects: 47
Study: 10572207

Group type: EXPERIMENTAL
Intervention: Formoterol 12 mg via Aerolizer
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Formoterol 12 mg via Turbuhaler
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8949363

Group type: EXPERIMENTAL
Intervention: L-arginine (30 g within 60 min)
Number of subjects: 85
Study: 8501156

Group type: EXPERIMENTAL
Intervention: Bombesin (BBS) infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK receptor antagonist)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control saline infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Loxiglumide treatment alone
Number of subjects: 9
Study: 3123598

Group type: EXPERIMENTAL
Intervention: Deprenyl 5 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29604160

Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg/d for 6 weeks
Number of subjects: 3668
Study: 27327537

Group type: EXPERIMENTAL
Intervention: Acupressure training plus sleep health instructions
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sleep health instructions only (Control)
Number of subjects: 90
Study: 26121892

Group type: EXPERIMENTAL
Intervention: Oral ketamine (5 mg/kg in 2 cc/kg apple juice)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Peritonsillar infiltration of ketamine (0.5 mg/kg)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (2 cc/kg apple juice)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Peritonsillar infiltration of ketamine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Oral ketamine
Number of subjects: 92
Study: 23691171

Group type: EXPERIMENTAL
Intervention: 0.1 µg C-Tb
Number of subjects: 151

Group type: COMPARATOR
Intervention: 2 TU PPD
Number of subjects: 151
Study: 21683078

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 19366101

Group type: EXPERIMENTAL
Intervention: Xianling Gubao capsules
Number of subjects: 50

Group type: COMPARATOR
Intervention: Calcitriol and Caltrate D 600
Number of subjects: 50
Study: 16630681

Group type: EXPERIMENTAL
Intervention: Information CD-Rom
Number of subjects: 60

Group type: COMPARATOR
Intervention: No Information CD-Rom
Number of subjects: 60
Study: 15599159

Group type: EXPERIMENTAL
Intervention: Arctic Sun Temperature Management System (Medivance, Louisville CO)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional water‐circulating cooling blanket (Cincinnati SubZero, Cincinnati OH)
Number of subjects: 47
Study: 11490105

Group type: EXPERIMENTAL
Intervention: Patient factors influencing social outcome after stroke
Number of subjects: 0
Study: 9935227

Group type: EXPERIMENTAL
Intervention: cisplatin (CDDP), dacarbazine (DTIC), interferon-alpha (IFN-alpha) +/− interleukin-2 (IL-2)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: cisplatin (CDDP), dacarbazine (DTIC), interferon-alpha (IFN-alpha) with IL-2
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: cisplatin (CDDP), dacarbazine (DTIC), interferon-alpha (IFN-alpha) without IL-2
Number of subjects: 7

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 7
Study: 7925516

Group type: EXPERIMENTAL
Intervention: Combination therapy (10 mg quinapril plus 12.5 mg HCTZ)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Monotherapy with 10 mg quinapril
Number of subjects: 368

Group type: COMPARATOR
Intervention: Monotherapy with 12.5 mg HCTZ
Number of subjects: 368
Study: 2509737

Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator at a dose of 0.05 mg/kg/hr (n = 4)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator at a dose of 0.025 mg/kg/hr (n = 4)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator (both doses)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Secondary procedures
Number of subjects: 8
Study: 1178359

Group type: EXPERIMENTAL
Intervention: binary feedback
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: real-time, proportional feedback
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: numerical, proportional feedback
Number of subjects: 32

Group type: COMPARATOR
Intervention: no feedback
Number of subjects: 32
Study: 28956183

Group type: EXPERIMENTAL
Intervention: Multimodal intervention consisting of time-skill training and compensation with time-assistive devices (TAD)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Educational intervention (Control)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Multimodal intervention consisting of time-skill training and TAD
Number of subjects: 38
Study: 28508180

Group type: EXPERIMENTAL
Intervention: Throat pack group (water-soaked throat pack gauze inserted in the mouth to occlude the oropharynx)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-throat pack group (no throat pack)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Throat pack group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-throat pack group
Number of subjects: 80
Study: 24983433

Group type: COMPARATOR
Intervention: ORIF
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ORIF + PSTA
Number of subjects: 31
Study: 22181689

Group type: EXPERIMENTAL
Intervention: DOX-COL + EDTA
Number of subjects: 30

Group type: COMPARATOR
Intervention: DOX-COL
Number of subjects: 30
Study: 20835965

Group type: EXPERIMENTAL
Intervention: High threat information with high coping information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High threat information with low coping information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low threat information with high coping information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low threat information with low coping information
Number of subjects: 0
Study: 17950970

Group type: EXPERIMENTAL
Intervention: Fluoxetine (10-60 mg/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sertraline (25-350 mg/d)
Number of subjects: 45
Study: 16029334

Group type: EXPERIMENTAL
Intervention: Calcipotriol scalp solution 50 microg mL(‐1) applied twice daily for 4 days prior to chemotherapy and continued for 14 days during each treatment cycle.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 4 days prior to chemotherapy and continued for 14 days during each treatment cycle.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined results of treatment groups (calcipotriol and vehicle).
Number of subjects: 24
Study: 14500162

Group type: EXPERIMENTAL
Intervention: Ropivacaine 3.75 mg/mL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg/mL
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 45
Study: 10656057

Group type: EXPERIMENTAL
Intervention: 8 g gamma‐CD (test)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 8 g maltodextrin (placebo)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of gamma‐CD and maltodextrin
Number of subjects: 24